Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method and reagent for treatment of diseases caused by expression of the c-myc gene

a technology of c-myc gene and reagent, which is applied in the field of method and reagent for treating diseases caused by expression of the cmyc gene, can solve the problems of destroying the ability to direct the synthesis of encoded proteins, and achieves the effects of prohibitive therapeutic cost, reduced treatment cost, and high specificity

Inactive Publication Date: 2004-02-19
RIBOZYME PHARMA INC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0010] Ribozymes act by first binding to a target RNA. Such binding occurs through the target RNA binding portion of a ribozyme which is held in close proximity to an enzymatic portion of the RNA which acts to cleave the target RNA. Thus, the ribozyme first recognizes and then binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After a ribozyme has bound and cleaved its RNA target it is released from that RNA to search for another target and can repeatedly bind and cleave new targets.
[0011] The enzymatic nature of a ribozyme is advantageous over other technologies, such as antisense technology (where a nucleic acid molecule simply binds to a nucleic acid target to block its translation) since the effective concentration of ribozyme necessary to effect a therapeutic treatment is lower than that of an antisense oligonucleotide. This advantage reflects the ability of the ribozyme to act enzymatically. Thus, a single ribozyme molecule is able to cleave many molecules of target RNA. In addition, the ribozyme is a highly specific inhibitor, with the specificity of inhibition depending not only on the base pairing mechanism of binding, but also on the mechanism by which the molecule inhibits the expression of the RNA to which it binds. That is, the inhibition is caused by cleavage of the RNA target and so specificity is defined as the ratio of the rate of cleavage of the targeted RNA over the rate of cleavage of non-targeted RNA. This cleavage mechanism is dependent upon factors additional to those involved in base pairing. Thus, it is thought that the specificity of action of a ribozyme is greater than that of antisense oligonucleotide binding the same RNA site.
[0020] The invention provides a class of chemical cleaving agents which exhibit a high degree of specificity for the mRNA causative of Burkitt's lymphoma or acute lymphocytic leukemia. Such enzymatic RNA molecules can be delivered exogenously or endogenously to infected cells. In the preferred hammerhead motif the small size (less than 40 nucleotides, preferably between 32 and 36 nucleotides in length) of the molecule allows the cost of treatment to be reduced.
[0021] The smallest ribozyme delivered for any type of treatment reported to date (by Rossi et al., 1992 supra) is an in vitro transcript having a length of 142 nucleotides. Synthesis of ribozymes greater than 100 nucleotides in length is very difficult using automated methods, and the therapeutic cost of such molecules is prohibitive. Delivery of ribozymes by expression vectors is primarily feasible using only ex vivo treatments. This limits the utility of this approach. In this invention, an alternative approach uses smaller ribozyme motifs (e.g., of the hammerhead structure, shown generally in FIG. 1) and exogenous delivery. The simple structure of these molecules also increases the ability of the ribozyme to invade targeted regions of the mRNA structure. Thus, unlike the situation when the hammerhead structure is included within longer transcripts, there are no non-ribozyme flanking sequences to interfere with correct folding of the ribozyme structure, as well as complementary binding of the ribozyme to the mRNA target.
[0022] The enzymatic RNA molecules of this invention can be used to treat human Burkitt's lymphoma, acute lymphocytic leukemia or precancerous conditions. Such treatment can also be extended to other related genes in nonhuman primates. Affected animals can be treated at the time of cancer detection or in a prophylactic manner. This timing of treatment will reduce the number of affected cells and disable cellular replication. This is possible because the ribozymes are designed to disable those structures required for successful cellular proliferation.

Problems solved by technology

Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method and reagent for treatment of diseases caused by expression of the c-myc gene
  • Method and reagent for treatment of diseases caused by expression of the c-myc gene
  • Method and reagent for treatment of diseases caused by expression of the c-myc gene

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0024] The drawing will first briefly be described.

[0025] Drawing

[0026] FIG. 1 is a diagrammatic representation of a hammerhead motif ribozyme showing stems I, II and III (marked (I), (II) and (III) respectively) interacting with a viral target region. The 5' and 3' ends of both ribozyme and target are shown. Dashes indicate base-paired nucleotides.

[0027] Target Sites

[0028] Ribozymes targeting selected regions of mRNA associated with tumor cell growth are chosen to cleave the target RNA in a manner which preferably inhibits translation of the RNA. Genes are selected such that inhibition of translation will preferably inhibit cell replication, e.g., by inhibiting production of a necessary protein. Selection of effective target sites within these critical regions of MRNA entails testing the accessibility of the target RNA to hybridization with various oligonucleotide probes. These studies can be performed using RNA probes and assaying accessibility by cleaving the hybrid molecule with...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
thickaaaaaaaaaa
thickaaaaaaaaaa
Login to View More

Abstract

The present invention relates to an enzymatic RNA molecule which cleaves mRNA derived from c-myc gene.

Description

[0001] This patent application is a continuation of Thompson, U.S. Ser. No. 08 / 192,943 filed Feb. 7, 1994, which is a continuation of Thompson, U.S. Ser. No. 07 / 936,422 filed Aug. 26, 1992, abandoned, all entitled "METHOD AND REAGENT FOR TREATMENT OF DISEASES CAUSED BY EXPRESSION OF THE c-MYC GENE". All of the above applications are hereby incorporated by reference herein in their entirety, including the drawings.BACKGROUND OF THE INVENTION[0002] This invention relates to methods for inhibition of growth of transformed cells, and inhibition of progression to a transformed phenotype in pre-neoplastic cells.[0003] Transformation is a cumulative process whereby normal control of cell growth and differentiation is interrupted, usually through the accumulation of mutations affecting the expression of genes that regulate cell growth and differentiation.[0004] Scanlon W091 / 18625, W091 / 18624, and W091 / 18913 describes a ribozyme effective to cleave oncogene RNA from the H-ras gene. This ribo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N15/113
CPCC12N15/113C12N15/1135C12N2310/121C12N2310/126C12N2310/123C12N2310/124C12N2310/122
Inventor THOMPSON, JAMES D.DRAPER, KENNETH G.
Owner RIBOZYME PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products